Vendor Intelligence Report: EHZ Peptides

Published 3 Jul 2026. 22-page investigative report on who is behind EHZ Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 51 Finnrick lab tests, EHZ Peptides records 44 pass and 7 fail, for an overall pass rate of 86%. The average is a starting point, not a verdict: retatrutide is the strongest documented line, tirzepatide is a more cautious GLP-1 read, while BPC-157 is the clear avoid signal and GHK-Cu carries a separate identity-failure concern. The full report shows how those product reads shift under stricter Finnrick grading views.

The non-lab file is unusually thin. EHZ is documented as a WhatsApp-first seller tied to a single +86 contact, with no canonical public website found: the obvious EHZ Peptides domain was still unregistered, Wayback had no captures, Delaware returned no exact-name entity, and Wyoming remained a narrower no-match observation because the registry session was still loading. That leaves buyers with limited ordinary recourse or impersonation protection.

The buyer problem is not only opacity. Field-captured certificates and product tables repeatedly describe vials by label, crimp, and cap color rather than durable batch identifiers, including a reviewed tirzepatide certificate with missing container-level identifiers. The public reputation surface is similarly narrow: an inactive GLP-1 Forum thread, no explicit Reddit mentions in the capture, Finnrick-derived indexing, and a gated PepChat lead the investigation could not directly enter.

Directional read: EHZ is most defensible for retatrutide, potentially workable for tirzepatide only when a current lot-linked COA can be matched to the vial, and poorly positioned for BPC-157 or unverified GHK-Cu.

Inside the full report:

  • Per-product laboratory breakdown, methodology-divergence charts, and rating trajectories for all four tested products
  • WHOIS, Wayback, Delaware, Wyoming, and OpenCorporates registry-path evidence with confidence limits
  • Certificate-level traceability review covering missing batch IDs, container identifiers, and best-before data
  • Community-surface review of GLP-1 Forum, Reddit, PeptideBenchmark, Finnrick profile, and the PepChat access gap
  • Affiliate and promotion scan across X, coupon pages, and public Reddit search, with closed-platform caveats
  • Buyer risk matrix separating retatrutide/tirzepatide from BPC-157 and GHK-Cu concerns

Risk assessment

  • Operational-opacity and buyer-recourse risk — high: No public website/domain/legal entity or owner located; sales route centers on a single +86 WhatsApp/PepChat channel, leaving buyers with limited recourse.
  • Traceability and batch-verification risk — high: Field captures and a reviewed certificate show absent batch/container IDs and no best-before data; vials cannot be reliably matched to COAs.
  • GHK-Cu identity-failure risk — high: GHK-Cu certificate 20251217-e-y75rmg6 recorded a 0.0/10 result with the warning that the sample did not contain GHK-Cu.
  • BPC-157 product-quality risk — high: BPC-157 has a 49.15% Finnrick rating with 2 pass / 2 fail, and field materials characterize the failures as severe underdosing.
  • Brand-confusion and authenticity-verification risk — medium: ehzpeptides.com was unregistered, unrelated EZ/Ez peptide pages appeared in searches, and no official-channel list or anti-counterfeit verification path was found.